Investors

Press Releases

Press Releases

Press Releases

Jul 12, 2021
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation Kymera anticipates IND submission for STAT3 degrader KT-333 in
PDF Version
Jun 21, 2021
Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
Data presented at the 16th ICML Meeting demonstrate KT-413’s potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model KT-413 shows synergistic activity in driving deep tumor regressions in
PDF Version
Displaying 1 - 10 of 28

Investor Contact

Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com 
+ 1 339.970.2843
 

Media Contact

media@kymeratx.com

Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762

Sign Up for Email Alerts